Medical therapy of epilepsy: When to initiate treatment and when to combine?

被引:28
作者
Brodie, MJ [1 ]
机构
[1] Univ Glasgow, Western Infirm, Epilepsy Unit, Glasgow G11 6NT, Lanark, Scotland
关键词
epilepsy; treatment; antiepileptic drugs; strategy;
D O I
10.1007/s00415-005-0735-x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Most patients reporting more than one well-documented or witnessed seizure require prophylactic antiepileptic (AED) therapy. Those with an underlying brain disorder and/or an abnormal electroencephalogram should probably be treated after their first event. The goal should be maintenance of a normal lifestyle by complete seizure control with no or minimal side-effects. Failure of the first AED due to lack of efficacy implies refractoriness. A policy of consecutive substitutions is unlikely to be an effective strategy. Thus, if the first or second monotherapy improves control but does not produce seizure freedom, an AED with different and perhaps multiple mechanisms of action should be added. Strategies for combining drugs should involve individual assessment of patient-related factors, including seizure type and epilepsy syndrome classifications coupled with an understanding of the pharmacology, side-effects and interaction profile of the AEDs. Reducing the dose of one or more AEDs may help accommodate the introduction of a second or third drug. An orderly approach to the pharmacological management and, when appropriate, surgical investigations for each epilepsy syndrome will optimise the chance of perfect seizure control and help more people achieve safer and more fulfilled lives.
引用
收藏
页码:125 / 130
页数:6
相关论文
共 36 条
[11]   Patients with refractory seizures [J].
Devinsky, O .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (20) :1565-1570
[12]   Response to first drug trial predicts outcome in childhood temporal lobe epilepsy [J].
Dlugos, DJ ;
Sammel, MD ;
Strom, BL ;
Farrar, JT .
NEUROLOGY, 2001, 57 (12) :2259-2264
[13]   Practice parameter: Temporal lobe and localized neocortical resections for epilepsy - Report of the quality standards subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons [J].
Engel, J ;
Wiebe, S ;
French, J ;
Sperling, M ;
Williamson, P ;
Spencer, D ;
Gumnit, R ;
Zahn, C ;
Westbrook, E ;
Enos, B .
NEUROLOGY, 2003, 60 (04) :538-547
[14]   Epilepsy after the first drug fails: substitution or add-on? [J].
Kwan, P ;
Brodie, MJ .
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2000, 9 (07) :464-468
[15]   Effectiveness of first antiepileptic drug [J].
Kwan, P ;
Brodie, MJ .
EPILEPSIA, 2001, 42 (10) :1255-1260
[16]   Phenobarbital for the treatment of epilepsy in the 21st century: A critical review [J].
Kwan, P ;
Brodie, TJ .
EPILEPSIA, 2004, 45 (09) :1141-1149
[17]   Early identification of refractory epilepsy. [J].
Kwan, P ;
Brodie, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (05) :314-319
[18]   Refractory epilepsy: a progressive, intractable but preventable condition? [J].
Kwan, P ;
Brodie, MJ .
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2002, 11 (02) :77-84
[19]   The mechanisms of action of commonly used antiepileptic drugs [J].
Kwan, P ;
Sills, GJ ;
Brodie, MJ .
PHARMACOLOGY & THERAPEUTICS, 2001, 90 (01) :21-34
[20]   Neuropsychological effects of epilepsy and antiepileptic drugs [J].
Kwan, P ;
Brodie, MJ .
LANCET, 2001, 357 (9251) :216-222